Janssen Pharmaceuticals and Vertex Pharmaceuticals have entered into an exclusive licence agreement to develop, manufacture and commercialise VX-787, an investigational medicine for treatment of influenza A.

VX-787 is an influenza A-specific, oral polymerase inhibitor developed to directly inhibit replication of the influenza A virus, including recent H1 and H5 influenza strains, based on in-vitro data.

Under the terms of the licensing agreement, Janssen also has the rights to develop, manufacture and commercialise VX-787’s back-up compound, VX-353, for treatment of influenza. Janssen has additional rights for these activities for certain other back-up compounds for treating and preventing this disease.

"This treatment has the potential to address a significant unmet medical need and to improve the well-being of patients everywhere."

VX-787 is currently in Phase II development and Vertex completed a Phase IIA study of VX-787 in 2013. The Phase IIA challenge study showed statistically significant improvements in viral and clinical measurements of influenza A infection and demonstrated clinical proof-of-concept.

Janssen and Vertex anticipate additional clinical trials to begin in the coming months.

Janssen infectious diseases and vaccines global therapeutic area head Johan Van Hoof said: "This treatment has the potential to address a significant unmet medical need and to improve the well-being of patients everywhere."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to Vertex, VX-787 has showed potent and rapid in-vitro antiviral activity on all the company tested influenza A strains to date, including oseltamivir (Tamiflu) resistant strains. Initial clinical assessments of VX-787 have also been promising.

In Phase I studies, the molecule was well-tolerated in healthy volunteers providing a pharmacokinetic profile supportive of once-daily dosing.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now